Appeal My Denial

Home › Guides › GLP-1 drug denied: Ozempic, Wegovy, Mounjaro or Zepbound

GLP-1 drug denied: Ozempic, Wegovy, Mounjaro or Zepbound

Reviewed October 26, 2026 · 8 min read

Short answer: First find out which kind of no you got. If your plan covers the drug but says you didn't meet its criteria (prior authorization, step therapy, BMI or diagnosis), ask for the written criteria and have your prescriber send the records that meet them. If your plan excludes weight-loss drugs, an appeal usually has to show a different covered use, such as diabetes, heart disease risk or sleep apnea. On Medicare, Part D can't cover drugs used for weight loss, but a CMS program called the Medicare GLP-1 Bridge covers some of them for $50 a month from July 1, 2026 through December 31, 2027.

Step 1: Find out which kind of “no” it is

GLP-1 denials fall into three groups, and each needs a different response:

Read the denial for the exact wording, or call and ask: “Is this drug excluded, or did I not meet the criteria? Please send me the criteria you used.” Job-based plans have to tell you the specific reason, the plan provision they relied on, and what information would complete the claim. They also have to give you, free on request, any internal rule or guideline they used and the documents relevant to your claim.

Step 2: Match the drug to its FDA-approved use

Plans often cover these drugs for some uses and not others, so the diagnosis on the prescription matters. Here's what the FDA has approved each one for:

If you have one of these other conditions, make sure your prescriber's request and records say so. A request for Zepbound for sleep apnea, or Wegovy for heart disease risk, can be treated differently from a request for weight loss.

Job-based and Marketplace plans

Coverage for weight loss is far from universal. In KFF's 2026 survey of employers, 18% of firms with 200 or more workers that offer health benefits covered GLP-1s for weight loss. Among those that did, 40% required people to meet with a dietitian, case manager or therapist, or join a lifestyle program. In KFF's look at 2024 HealthCare.gov plans, Wegovy was covered by just 1% of plans' drug lists, and all of the plans that covered GLP-1s approved for obesity required prior authorization.

What to do:

  1. Get the criteria. Ask for the written prior authorization or coverage policy for the drug, then go through it line by line with your prescriber.
  2. Send the missing pieces. Common ones: your diagnosis, height, weight and BMI history, related conditions, other drugs you've tried and what happened, and proof of any required lifestyle program.
  3. If the drug isn't on the list, plans that must cover essential health benefits (most individual and small-group plans, including Marketplace plans) have to offer an exception process. A standard request is decided within 72 hours, or 24 hours when your health is seriously at risk, and if it's denied you can ask for an independent review.
  4. Appeal in writing if the answer is still no. For job-based and Marketplace plans you generally have at least 180 days. Check your deadline. Denials based on medical judgment can then go to external review.

Medicare: what Part D can and can't cover

By law, Medicare drug plans (Part D) can't cover drugs when they're used for weight loss, even for obesity. That rule is about the use, not the drug. Part D plans must keep covering GLP-1 drugs for uses Medicare can cover, such as type 2 diabetes, Zepbound for moderate to severe sleep apnea in adults with obesity, and Wegovy to lower heart attack and stroke risk in adults with heart disease and obesity or overweight. For those uses, plans follow their normal rules, including prior authorization, and their normal formulary exception process. If your plan denies one of these, ask for a coverage determination and appeal: how Medicare drug exceptions and appeals work.

The Medicare GLP-1 Bridge (July 2026 to December 2027)

The Medicare GLP-1 Bridge is a short-term CMS program that runs from July 1, 2026 through December 31, 2027. It runs outside the regular Part D benefit. According to Medicare.gov:

CMS says the Bridge doesn't change your Part D appeal rights. Medicare.gov doesn't describe a separate appeal process for the Bridge, so if a Bridge request is turned down, call 1-800-MEDICARE and ask what to do next. What happens after 2027 hasn't been announced; CMS has delayed a planned longer-term program called BALANCE, which had been set to start in Part D in January 2027. Free one-on-one help is available from your State Health Insurance Assistance Program (SHIP).

Medicaid

State Medicaid programs choose whether to cover drugs for weight loss, but they must cover drugs approved for diabetes. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, and coverage usually comes with prior authorization. Check your state's preferred drug list, and if you're denied, appeal through Medicaid.

What your prescriber's request should include

Compounded and cash-price options

The FDA declared the shortages of tirzepatide injection (first on October 2, 2024, confirmed December 19, 2024) and semaglutide injection (February 21, 2025) resolved. The FDA notes that compounded drugs are not FDA-approved. If you pay cash through a discount program such as TrumpRx, KFF notes those payments don't count toward your insurance deductible or out-of-pocket maximum.

Your next question

Prescription drug denied: how to ask for an exceptionYour plan won't cover a drug, or wants you to try a cheaper one first? Ask for an exception. Many plans must…Denied because prior authorization wasn't obtainedA CO-197 'no prior authorization' denial is often winnable. Emergency care generally needs no prior…How to appeal a Medicare Advantage denialMedicare Advantage gives you 65 days to ask for a reconsideration. Here's how to file, how fast the plan must… Check your appeal deadlinePick your plan type and the date on your letter. Free, and nothing is sent anywhere.

Common questions

Why was Ozempic approved for my friend but denied for me?

Ozempic is FDA-approved for type 2 diabetes and related heart and kidney risk, not for weight loss. Plans often cover it only with a type 2 diabetes diagnosis. Wegovy and Zepbound are the versions approved for weight management, and many plans exclude or restrict them.

Does Medicare cover Wegovy or Zepbound?

Part D can't cover drugs used for weight loss, but it can cover Wegovy to lower heart attack and stroke risk in adults with heart disease and obesity or overweight, and Zepbound for moderate to severe sleep apnea. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers Wegovy, Zepbound KwikPen and Foundayo for eligible people for a $50 monthly copay.

Can I appeal if my plan excludes weight-loss drugs?

You can always appeal, but an exclusion is hard to overturn by arguing you need to lose weight. Ask whether the drug could be covered for another FDA-approved use you have, such as diabetes, heart disease risk or sleep apnea, and have your prescriber document it.

Let the app write it for you

Snap a photo of your denial letter. Appeal My Denial tells you why you were denied, your exact deadline, and drafts the appeal letter, plus the note for your doctor.

Coming soon to the App Store

Sources